Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dow Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.66 (market cap $39.89B), while Dow Inc trades at $30.22 (market cap $20.92B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DOW | |
|---|---|---|
Market Cap | $39.89B | $20.92B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $41.87 |
52-Week Low | $278.09 | $20.65 |
Enterprise Value | $38.15B | $36.70B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DOW trades at $29.03, up 1.86% today, but remains in a bearish technical trend with support near $28. The company reported a net loss of $2.62 billion in 2025, with negative profit margins and declining revenue, though it has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $36.11 price target, indicating potential upside if fundamentals improve.
The outlook is cautious; while liquidity supports dividends and the stock trades below book value, persistent losses and high debt pose significant risks. Investor sentiment is mixed amid broader market volatility, with earnings performance being the critical factor for any sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
